Screener
Alamar Biosciences ALMR Americas — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alamar Biosciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026.
- Filed
- May 8, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-213424
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| United States | $14,905 | $9,469 |
| Europe, Middle East and Africa (excluding United Kingdom) | 3,972 | 1,422 |
| United Kingdom | 3,462 | 1,730 |
| Asia-Pacific | 2,409 | 450 |
| Americas (excluding United States) | 1,287 | 20 |
| Total | $26,035 | $13,091 |
Item 1. Financial Statements
FAQ
- What is Alamar Biosciences's americas — revenue?
- Alamar Biosciences (ALMR) reported americas — revenue of $1.29M in Q1 2026.
- What does americas — revenue mean?
- This metric represents the total revenue generated from customers located within the Americas region, excluding any sales-related taxes collected on behalf of government authorities. It reflects the commercial adoption and market penetration of the company's proteomics platform and NULISA technology within this specific geographic territory. Tracking this figure allows investors to assess the regional growth trajectory and the effectiveness of sales and distribution efforts in the North and South American markets.
Ask your AI about Alamar Biosciences's americas — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude